Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Govt Plans Switch to 6-Dose Syringes for Elderly “Sometime in May”: Kono
The Japanese government plans to switch to special syringes that can extract six doses from a single vial of Pfizer’s COVID-19 vaccine in its elderly inoculation program from “sometime in May,” vaccination campaign minister Taro Kono said on March 26.…
To read the full story
Related Article
- Vaccines for All People to Be Delivered to Local Govts by October-End: Kono
June 30, 2021
- Japan Eyes Different Supply Routes for Non-Pfizer COVID-19 Vaccines: Kono
April 26, 2021
- 1st Vaccine Doses to Be Delivered for Half of Elderly by May: Kono
April 5, 2021
- All Municipalities to Get 2nd Doses for HCPs by Week of May 10: Minister
March 15, 2021
REGULATORY
- Japan OKs Coverage for Susmed Insomnia App, Shionogi ADHD Therapy App
May 15, 2026
- MHLW’s Mori Vows to Make Japan Pharma Market “More Attractive”
May 15, 2026
- MHLW Official Says US MFN Policy Could Be Taken Up by Chuikyo
May 15, 2026
- Oncolys’ Telomelysin Up for Japan Panel Review on May 21
May 15, 2026
- Japan to Launch CEA “Technical Discussions” under MHLW Research Group
May 14, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…